Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
JBI-802 by Jubilant Therapeutics for Neuroendocrine Tumors: Likelihood of Approval
JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase...
JBI-802 by Jubilant Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
JBI-802 by Jubilant Therapeutics for Myeloproliferative Disorders: Likelihood of Approval
JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase...
JBI-802 by Jubilant Therapeutics for Solid Tumor: Likelihood of Approval
JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
JBI-802 by Jubilant Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
JBI-802 by Jubilant Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
JBI-802 by Jubilant Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
JBI-802 by Jubilant Therapeutics for Prostate Cancer: Likelihood of Approval
JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...